資源 » 參考數據庫 » 客戶發表文獻

至今，GenScript的服務及產品已被Cell, Nature, Science, PNAS等1300多家生物醫藥類雜志引用近萬次，處于行業領先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學等約400家全球著名機構使用GenScript的基因合成、多肽服務、抗體服務和蛋白服務等成功地發表科研成果，再次證明GenScript 有能力幫助業內科學家Make research easy.

miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells

Oncotarget. 2017-04;

ZhuoZhihong, YuHu

Products/Services Used	Details	Operation
Catalog Antibody	… obtained from Invitrogen (Pontoise, France). Antibodies against LC3-II/I, PTEN, pAKT, pmTOR, beclin1 and GAPDH were purchased from Genscript Biotechnology (USA). Cell lines and culture conditions. A PR-EC sub-cell line …	Get A Quote

摘要

miR-205 is significantly up-regulated in endometrioid adenocarcinoma. In this study， the significant anticancer effect of a miR-205 inhibitor was investigated in both endometrial carcinoma and progesterone-resistant endometrial carcinoma cells.